OOIR: Observatory of International Research

Papers

(The TQCC of Drugs is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	471
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	407
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	245
Targeting DNA Damage Response Deficiency in Thoracic Cancers	216
New Therapies on the Horizon for Primary Biliary Cholangitis	213
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,	197
Eftrenonacog Alfa: A Review in Haemophilia B	189
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	162
Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms	151
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	149
Acknowledgement to Referees	142
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	132
Aprocitentan: First Approval	129
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	129
Vorasidenib: First Approval	127
Senaparib: First Approval	120
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	117
Teclistamab: First Approval	112
Spesolimab for the Treatment of Generalized Pustular Psoriasis	111
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	108
Epcoritamab: First Approval	108
Ivarmacitinib Sulfate: First Approval	105
Olipudase Alfa: First Approval	102
Cosibelimab: First Approval	102
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms	96

Tolebrutinib: First Approval	92
Drugs in Development to Manage Acute Pain	91
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?	88
Lenacapavir: First Approval	88
Danicopan: First Approval	88
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	86
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	85
Repotrectinib: First Approval	85
Acoltremon: First Approval	84
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	84
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	83
Androgenetic Alopecia: Therapy Update	80
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema	80
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	78
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	73
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	73
Mazdutide: First Approval	72
Cancer Pain Treatment Strategies in Patients with Cancer	70
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	69
Mosunetuzumab: First Approval	69
Olverembatinib: First Approval	68
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	67
Managing Burning Mouth Syndrome: Current and Future Directions	67
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?	65
Correction to: Tapinarof Cream 1%: First Approval	65
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	64
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	64
Correction to: Prevention and Treatment of Monkeypox	61
Taletrectinib: First Approval	60
Sunvozertinib: First Approval	59
The Place of Cannabinoids in the Treatment of Gynecological Pain	59
Dorzagliatin: First Approval	58
Pozelimab: First Approval	58
Tovorafenib: First Approval	57
Ifupinostat: First Approval	57
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	56
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer	56
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	53
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	53
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	51
Correction to: Concizumab: First Approval	51
Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies	50
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	49
Pan-JAK Inhibition Across Chronic Hand Eczema and Other Cutaneous Diseases: An Updated Review on Topical Delgocitinib	49
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	49
Correction to: Remdesivir: A Review in COVID-19	48
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	48
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	47
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	46
Tirzepatide: A Review in Type 2 Diabetes	46

Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review	46
Aumolertinib: A Review in Non-Small Cell Lung Cancer	45
Birch Bark Extract: A Review in Epidermolysis Bullosa	45
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	44
Givinostat: First Approval	44
Gepirone Extended-Release: First Approval	43
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	43
Asciminib: First Approval	43
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	41
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	41
Ozoralizumab: First Approval	41
Catumaxomab: First Approval	41
Correction: Teprotumumab: A Review in Thyroid Eye Disease	39
Atrasentan: First Approval	39
Current and Emerging Treatments for Acid Sphingomyelinase Deficiency	39
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	38
Fezolinetant: First Approval	38
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	37
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	37
Ensitrelvir Fumaric Acid: First Approval	37
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	37
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	37
Futibatinib: First Approval	36
Avacincaptad Pegol: First Approval	36
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	36
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	35
Lotilaner Ophthalmic Solution 0.25%: First Approval	34
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	34
Imetelstat: First Approval	34
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	34
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis	34
Correction: Iptacopan: First Approval	34
Eye Involvement and Management in Inherited Epidermolysis Bullosa	34
Zeprumetostat: First Approval	33
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	33
Managing Pain in Fibromyalgia: Current and Future Options	33
Zastaprazan: First Approval	32
Gastrointestinal Dysfunction in Parkinson’s Disease	32
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	32
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	32
Tebentafusp: First Approval	32
Beremagene Geperpavec: First Approval	32
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	32
Acknowledgement to Referees	31
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	31
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	30
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues	30
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	30
Mavorixafor: First Approval	30
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	30
Retifanlimab: First Approval	30
Crinecerfont: First Approval	30
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”	30
Sepiapterin: First Approval	29
Nogapendekin alfa Inbakicept: First Approval	29
Diagnosis and Treatment of AL Amyloidosis	29
Revumenib: First Approval	29
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	29
Correction to: Abrocitinib: First Approval	28
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	28
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	28
Ravulizumab: A Review in Generalised Myasthenia Gravis	27
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	27
Correction to: Sparsentan: First Approval	27
Onradivir: First Approval	27
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	27
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	27
Correction to: Spesolimab: First Approval	27
Correction: Zastaprazan: First Approval	27
Methadone for Cancer Pain Management in Children: A Review of Literature	26
Zolbetuximab: First Approval	26
Remdesivir: A Review in COVID-19	26
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	26
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	26
Keverprazan Hydrochloride: First Approval	26
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	26